Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Talimogene laherparepvec (T-VEC)
Treatment for Malignant skin melanoma
Typical Dosage: Intralesional injection. Initial dose 10^6 PFU/mL, subsequent doses 10^8 PFU/mL. Up to 4 mL per visit.
Effectiveness
75%
Safety Score
60%
Clinical Trials
4
Participants
1.2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Intralesional injection. Initial dose 10^6 PFU/mL, subsequent doses 10^8 PFU/mL. Up to 4 mL per visit.
Time to Effect
2-4 months
Treatment Duration
6 months or until progression
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$7,000
Side Effect Mgmt:$3,000
Total Annual:$90,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$280,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$450,000
Cost per Remission
$1,125,000
Comparison vs Ipilimumab
Cost Difference
$-20,000/year
Less expensive
QALY Difference
-0.20 QALYs
Worse outcomes
Dominance
No dominance
Talimogene laherparepvec (T-VEC) Outcomes
for Malignant skin melanoma
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+20%
Remission Rate
+8%
Common Side Effects
Fatigue
+55%
Chills
+45%
Fever
+45%
Nausea
+35%
Flu-like symptoms
+25%
Injection site pain/cellulitis
+25%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Talimogene laherparepvec (T-VEC) in Malignant skin melanoma
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978625ACTIVE NOT RECRUITINGPHASE2
68 participants
INTERVENTIONAL
Los Angeles, United States +35 more
Started: Sep 27, 2017
Completed Clinical Trials
2 completed trials for Talimogene laherparepvec (T-VEC) in Malignant skin melanoma
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
NCT00289016COMPLETEDPHASE2
50 participants
INTERVENTIONAL
La Jolla, United States +7 more
Started: Dec 1, 2005
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
NCT02574260COMPLETEDPHASE2
3 participants
INTERVENTIONAL
Started: Aug 1, 2008